Urotronic’s drug-coated balloon technology is utilised in interventional urology. Credit: Pixel-Shot / Shutterstock.com.

Laborie Medical Technologies has entered a definitive agreement for the acquisition of medical device company Urotronic in a deal valued at up to $600m.

As per the deal, Laborie will make an upfront cash payment of $255m to Urotronic.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Urotronic is entitled to receive potential commercial and reimbursement milestone payments of up to an additional $345m. 

The net value of the existing minority stake of Laborie in Urotronic will be $232m and the net upfront and milestone payments will be up to $314m.

The latest deal is part of Laborie’s strategy to strengthen its urology portfolio and is in line with the company’s plan to offer validated solutions to patients and physicians across the globe.

Urotronic’s Optilume paclitaxel drug-coated balloon technology is used in interventional urology, including for the treatment of urethral strictures and benign prostatic hyperplasia (BPH).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

This technology offers a less invasive treatment option for several patients suffering from such ailments across the globe.

Laborie Medical Technologies president and CEO Mike Frazzette said: “There has never been a minimally invasive, combination drug-device therapy like Optilume before, leading to a highly disruptive paradigm change for physicians treating urethral strictures and BPH. 

“With this acquisition, we will continue to advance innovative technologies by meeting multiple unmet medical needs and, in doing so, provide solutions that preserve and restore human dignity.”

Laborie will also make an equity investment of $5m in Urotronic spin-out GIE Medical in tandem with the latest takeover.

GIE Medical is a clinical-stage company that focuses on the development of drug-coated balloon technology to treat strictures in the gastrointestinal tract, similar to Optilume.

In October 2020, Laborie and Urotronic announced a multi-faceted, strategic partnership.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact